CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [81]
In the citing paper
“but correlations between in vivo CSF tau biomarkers and tau aggregates in postmortem tissue are weaker (11).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [11]
In the citing paper
“levels of CSF tau and phosphorylated tau (ptau) species are elevated in DAT8, 13, 14 and are hypothesized to reflect the presence of neurofibrillary tangles and/or neurodegeneration,15, 16 although not all studies support this conclusion.17”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [16]
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“A staging system of Alzheimer’s-associated neurofibrillary pathology using immunohistochemistry and AT8 has been suggested (Braak et al., 2006).”
BackgroundMethodSelf-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“Whereas NFTs and neuritic processes are composed of fibrils containing phosphorylated tau, plaques consist mostly of fibrillous beta-amyloid (Grundke-Iqbal et al., 1986; Lee et al., 1991; Dickson, 1997).”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and Harald Hampel1 1Deme…”
BackgroundMethodResultInfluentialSelf-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
Items 401–500 of 584
Ekuni, D., Endo, Y., Tomofuji, T., Azuma, T., Irie, K., Kasuyama, K., & Morita, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074966 · Cited by 17
Enhancing attention in neurodegenerative diseases: current therapies and future directions
Sharma, K., Davis, T. L., & Coulthard, E. J. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0016 · Cited by 17
Sex and gender differences in dementia
Salwierz, P., Davenport, C., Sumra, V., Iulita, M. F., Ferretti, M. T., & Tartaglia, M. C. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.002 · Cited by 17
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough
McEvoy, L. K., & Brewer, J. B. (2012) · Imaging in Medicine · doi:10.2217/iim.12.27 · Cited by 17
Increased CSF tau level is correlated with decreased lamina cribrosa thickness
Lee, E. J., Kim, T., Lee, D. S., Kim, H., Park, Y. H., Kim, J.-E., Lee, J. W., & Kim, S. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0169-3 · Cited by 15
Fjell, A. M., & Walhovd, K. B. (2011) · The Neuroscientist · doi:10.1177/1073858410392586 · Cited by 19
Kaipainen, A. L., Jääskeläinen, O., Liu, Y., Haapalinna, F., Nykänen, N., Vanninen, R. L., Koivisto, A. M., Julkunen, V., Remes, A. M., & Herukka, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200175 · Cited by 19
Mazzeo, S., Ingannato, A., Giacomucci, G., Bagnoli, S., Cavaliere, A., Moschini, V., Balestrini, J., Morinelli, C., Galdo, G., Emiliani, F., et al. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07065-4 · Cited by 14
Cell-free RNA signatures predict Alzheimer’s disease
Cisterna‐García, A., Beric, A., Ali, M., Pardo, J. A., Chen, H., Fernández, M. V., Norton, J. B., Gentsch, J., Bergmann, K., Budde, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108534 · Cited by 14
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 27
Koric, L., Félician, O., & Ceccaldi, M. P. (2011) · Revue Neurologique · doi:10.1016/j.neurol.2010.10.007 · Cited by 19
Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
Zetterberg, H., Mattsson, N., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/163065 · Cited by 16
Maldonado, H., Ortiz-Riaño, E., Krause, B. J., Barriga, A., MEDINA, F., Pando, M. E., Alberti, C., Kettlun, A. M., Collados, L., García, L., et al. (2008) · Biological Research · doi:10.4067/s0716-97602008000300001 · Cited by 14
Use of CSF biomarkers in Alzheimer's disease clinical trials
Blennow, K., & Zetterberg, H. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0043-8 · Cited by 15
Tau proteins in the cerebrospinal fluid of patients with subacute sclerosing panencephalitis
Yüksel, D., Yilmaz, D., Uyar, N. Y., Şenbil, N., Gürer, Y., & Anlar, B. (2009) · Brain and Development · doi:10.1016/j.braindev.2009.11.009 · Cited by 14
Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology
Ojakäär, T., & Koychev, I. G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.772836 · Cited by 14
Dragović, I. R., Popović, N., Ždralević, M., Radulović, L., Vuković, T., Marzano, F., Tullo, A., & Radunović, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220676 · Cited by 18
Hassaan, P. S., Dief, A. E., Zeitoun, T. M., Baraka, A., Deacon, R. M. J., & Elshorbagy, A. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220720 · Cited by 19
Lilamand, M., Hourrègue, C., & Paquet, C. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2019.12.006 · Cited by 13
Gabelle, A., Roche, S., & Lehmann, S. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2008.05.004 · Cited by 14
Cerebrospinal Fluid Sphingomyelins in Alzheimer’s Disease, Neurodegeneration, and Neuroinflammation1
Morrow, A. R., Panyard, D. J., Deming, Y. K., Jonaitis, E. M., Dong, R., Vasiljevic, E., Betthauser, T. J., Kollmorgen, G., Suridjan, I., Bayfield, A., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220349 · Cited by 15
Role of CSF Biomarkers in the Diagnosis of Prodromal Alzheimer‘s Disease
Parnetti, L., & Chiasserini, D. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.48 · Cited by 13
Biomarkers in Alzheimer’s disease
Demarin, V., Zavoreo, I., Kes, V. B., & Šimundić, A.-M. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.139 · Cited by 19
Cerebrospinal fluid in the dementias
Zetterberg, H., Rohrer, J. D., & Schott, J. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00006-x · Cited by 18
Malpas, C. B., Saling, M. M., Velakoulis, D., Desmond, P. M., & O'Brien, T. J. (2015) · Neurodegenerative Diseases · doi:10.1159/000438924 · Cited by 12
Nanoparticle approaches for the renin-angiotensin system
Hettiarachchi, S. D., Kwon, Y. M., Omidi, Y., & Speth, R. C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16951 · Cited by 14
Lu, K. P., & Zhou, X. Z. (2024) · Science Signaling · doi:10.1126/scisignal.adi8743 · Cited by 12
Tau biomarkers for neurodegenerative diseases: Current state and perspectives
Vacchi, E., Ruíz‐Barrio, I., & Melli, G. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107772 · Cited by 12
Leko, M. B., Perković, M. N., Španić, E., Štrac, D. Š., Pleić, N., Vogrinc, Ž., Gunjača, I., Bežovan, D., Erjavec, G. N., Klepac, N., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10123118 · Cited by 11
Ba, M., Yu, G., Kong, M., Liang, H. W., & Yu, L. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0129-5 · Cited by 11
Fluid Biomarkers of Frontotemporal Lobar Degeneration
van der Ende, E. L., & Swieten, J. C. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_9 · Cited by 12
Cantero, J. L., Atienza, M., Sánchez‐Juan, P., Rodríguez‐Rodríguez, E., Vázquez‐Higuera, J. L., Pozueta, A., González‐Suárez, A., Vilaplana, E., Pegueroles, J., Montal, V., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.010 · Cited by 12
van der Spoel, E., van Vliet, N. A., & van Heemst, D. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100964 · Cited by 12
Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
Lowe, A. J., Sjödin, S., Rodrigues, F. B., Byrne, L. M., Blennow, K., Tortelli, R., Zetterberg, H., & Wild, E. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233820 · Cited by 11
Supervised Deep Tree in Alzheimer’s Disease
Yu, X., Zhang, L., Lyu, Y., Liu, T., & Zhu, D. (2023) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi53787.2023.10230742 · Cited by 12
Vergani, A. A., Mazzeo, S., Moschini, V., Burali, R., Lassi, M., Amato, L. G., Carpaneto, J., Salvestrini, G., Fabbiani, C., Giacomucci, G., et al. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103760 · Cited by 12
Jeyabalan, J. B., Vignesh Pandi, A., Sankar, V., Sivasamy, R., Dhanasekaran, M., & Justin, A. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08421-2 · Cited by 11
Heegaard, N. H. H., Østergaard, O., Bahl, J. M. C., Overgaard, M., Beck, H. C., Rasmussen, L. M., & Larsen, M. R. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400137 · Cited by 10
Tauomics and Kinetics in Human Neurons and Biological Fluids
Zetterberg, H. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.030 · Cited by 11
Centiloid scale analysis for 18F-THK5351 PET imaging in Alzheimer’s disease
Yamao, T., Miwa, K., Wagatsuma, K., Shigemoto, Y., Sato, N., Akamatsu, G., Ito, H., & Matsuda, H. (2021) · Physica Medica · doi:10.1016/j.ejmp.2021.02.017 · Cited by 10
Activity-dependent release of phosphorylated human tau from Drosophila neurons in primary culture
Ismael, S., Sindi, G., Colvin, R. A., & Lee, D. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101108 · Cited by 15
Challenges in the development of companion diagnostics for neuropsychiatric disorders
Nikolcheva, T., Jäger, S., Bush, T. A., & Vargas, G. A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.67 · Cited by 10
Borroni, B., Cerini, C., Archetti, S., Premi, E., Cosseddu, M., Ferrari, M., Bellelli, G., Gasparotti, R., Caimi, L., Luca, M. D., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101407 · Cited by 10
Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease
Safransky, M., Groh, J. R., Blennow, K., Zetterberg, H., Tripodis, Y., Martin, B. M., Weller, J. L., Asken, B. M., Rabinovici, G. D., Qiu, W. W. Q., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209866 · Cited by 10
Mazahir, F., Rahi, V., Kaundal, R. K., Alam, M. I., & Yadav, A. K. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158197 · Cited by 10
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
Biomarker Research in Multiple Sclerosis: Addressing Axonal Damage and Heterogeneity
Teunissen, C. E., Killestein, J., & Giovannoni, G. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.1.111 · Cited by 9
Szalárdy, L., Zádori, D., Klivènyi, P., & Vécsei, L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160037 · Cited by 11
From mild cognitive impairment to prodromal Alzheimer disease: A nosological evolution
Molinuevo, J. L., Valls‐Pedret, C., & Rami, L. (2010) · European Geriatric Medicine · doi:10.1016/j.eurger.2010.05.003 · Cited by 19
Laboratory biomarkers in Alzheimer’s disease
Steinerman, J. R., & Honig, L. S. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0059-6 · Cited by 10
Yakushev, I., Bartenstein, P., Siessmeier, T., Hiemke, C., Scheurich, A., Lotz, J., Fellgiebel, A., & Müller, M. J. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000320206 · Cited by 9
“Tauopathy and loss of synaptic activity/density are major early events in the pathogenesis of Alzheimer’s disease (AD). These characteristic AD lesions can be quantified in vivo using examination of cerebrospinal fluid (CSF) and positron emission tomography with 18 F-fluorodeoxyglucose (FDG-PET) [”
BackgroundThe Aged Dog as a Natural Model of Alzheimer’s Disease Progression
Araujo, J. A., Baulk, J., & de Rivera, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53219-6_4 · Cited by 9
Qiu, C., Li, Z., Leigh, D. A., Duan, B., Stucky, J. E., Kim, N., Xie, G., Lu, K. P., & Zhou, X. Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1343962 · Cited by 9
Repetitive Behaviors in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Polin, C., Gellé, T., Auditeau, E., Adou, C., Clément, J., & Calvet, B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230380 · Cited by 11
Cerebrospinal Fluid β-Amyloid and Dynabridging in Alzheimer's Disease Drug Development
Ereshefsky, L., Jhee, S. S., Yen, M., Moran, S., Pretorius, S., & Adams, J. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.39 · Cited by 8
Biomarkers for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00007-0 · Cited by 9
Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic
Stiffel, M., Bergeron, D., Amari, K. M., Poulin, É., Roberge, X., Meilleur‐Durand, S., Sellami, L., Molin, P., Nadeau, Y., Fortin, M., et al. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.67 · Cited by 10
What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta, D., Initiative, A. D. N., Moullart, V., Schraen‐Maschke, S., Devendeville, A., Meyer, M.-É., & Godefroy, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150829 · Cited by 7
Role of proline‐rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease
Kumar, R. K., Tiwari, V., & Dey, S. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15569 · Cited by 10
When Does Alzheimer’s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-Á., Cervera‐Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19305 · Cited by 8
Santillán-Morales, V., Rodríguez-Espinosa, N., Muñoz‐Estrada, J., Alarcón-Elizalde, S., Acebes, Á., & Benítez‐King, G. (2024) · Brain Sciences · doi:10.3390/brainsci14010046 · Cited by 12
Bruno, D., Grothe, M. J., Nierenberg, J. J., Teipel, S. J., Zetterberg, H., Blennow, K., & Pomara, N. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.002 · Cited by 8
Self-citationMild Cognitive Impairment Due to Alzheimer Disease is Less Likely Under the Age of 65
Shin, S., Kim, J. H., Cho, J. H., Kim, G. S., Choi, S., & Lee, J. H. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000044 · Cited by 8
Lee, J. K., Wang, K., Park, M. H., Kim, N., Lee, J. Y., Jin, H. K., Kim, I.-S., Lee, B.-H., & Bae, J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.06.041 · Cited by 7
Kim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective
Eratne, D., Collins, S. J., Nestor, P. J., Pond, D. C., Velakoulis, D., Yates, M. W., & Masters, C. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1488494 · Cited by 7
Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches
Tunalı, N. E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83153 · Cited by 10
Biomarker identification for diagnosis of Alzheimer's disease
Pelech, S. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.5.577 · Cited by 6
Olsson, B., Schott, J. M., Blennow, K., & Zetterberg, H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341311 · Cited by 7
Hyperexcitability in Aging Is Lost in Alzheimer’s: What Is All the Excitement About?
Lockwood, C. T., & Duffy, C. J. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa163 · Cited by 5
EEG Biomarker for Alzheimer’s Disease
Algın, D. İ., Adapınar, D. Ö., & Erdinç, O. O. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93711 · Cited by 7
Iqbal, K., Chohan, M. O., & Grundke, I. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15215 · Cited by 6
Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data
Guhra, M., Thomas, C., Boedeker, S., Kreisel, S. H., Drießen, M., Beblo, T., Ohrmann, P., & Toepper, M. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.11.008 · Cited by 6
Alzheimer's Disease-Related Lesions
Alafuzoff, I. I. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129024 · Cited by 5
Self-citationCan agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
del Campo, M., Zuroff, L. R., Jiménez, C. R., Scheltens, P., & Teunissen, C. E. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.008 · Cited by 8
Clinical Use of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
Zetterberg, H., Lunn, M. P., & Herukka, S. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.47 · Cited by 6
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab
Russu, A., Samtani, M. N., Xu, S. X., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S. V., Liu, E., Brashear, H. R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151065 · Cited by 7
Nabizadeh, F., Salehi, N., Ramezannezhad, E., Sadeghmousavi, S., & Khalili, E. (2022) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_77_22 · Cited by 6
Malpas, C. B., Saling, M. M., Velakoulis, D., Desmond, P. M., Hicks, R. J., Zetterberg, H., Blennow, K., & O'Brien, T. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170250 · Cited by 5
Neuropsychological Parameters as Potential Biomarkers for Alzheimer’s Disease
Wu, J., Yu, Y., & Yang, J. (2012) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-012-0007-4 · Cited by 5
Prakash, R. S., McKenna, M. R., Gbadeyan, O., Andridge, R., Scharre, D. W., & Initiative, A. D. N. (2020) · medRxiv · doi:10.1101/2020.10.13.20211375 · Cited by 5
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 5
Patwekar, F., Patwekar, M., Wei, L. S., Sharma, R., Varghese, R., & Mohammed, A. (2026) · Human Cell · doi:10.1007/s13577-026-01368-2 · Cited by 4
Jang, J., & Kim, S. (2019) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2019.1.1 · Cited by 4
Cui, J., Zufferey, V., & Kherif, F. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000225 · Cited by 5
Neurobiologische Frühdiagnostik der Alzheimer-Krankheit
Hampel, H. J., Teipel, S., & Bürger, K. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2317-x · Cited by 5
Self-citationCSF P-Tau 231 as Biomarker in Alzheimer's Disease
Mukherjee, A., & Biswas, A. (2022) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_858_22 · Cited by 5
Zhang, C., Tai, Y., Kong, M., Jia, P., Ma, G., Ba, M., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322196 · Cited by 5
The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease.
Grari, O., Elmoujtahide, D., Sebbar, E.-H., & Choukri, M. A. (2023) · PubMed Central · Cited by 3
Scianatico, G., Manippa, V., Zacà, D., Jovicich, J., Tafuri, B., Rivolta, D., & Logroscino, G. (2024) · Current Alzheimer Research · doi:10.2174/0115672050330903240919074725 · Cited by 4
Sanami, S., Intzandt, B., Huck, J., Villeneuve, S., Iturria‐Medina, Y., Gauthier, C. J., & Prevent-Ad Research Group (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.04.011 · Cited by 4
Plasma Amyloid-β in Patients with Tangier Disease
Shahim, P., Bochem, A. E., Mattsson, N., Lautner, R., Blennow, K., Hovingh, G. K., Motazacker, M. M., & Zetterberg, H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122425 · Cited by 4
Ewers, M., Insel, P. S., Jagust, W. J., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Petersen, R. C., Schuff, N. W., & Weiner, M. W. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.010 · Cited by 3
Self-citationalzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Alzheimer's Disease Longitudinal Change in CSF Biomarkers in Autosomal-Dominant
Fagan, A. M. (2014) · Cited by 3
Tavares-Júnior, J. W. L., Ciurleo, G. C. V., Feitosa, E. D. A. A. F., Oriá, R. B., & Braga‐Neto, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231368 · Cited by 3
A REVIEW OF BIOCHEMICAL MARKERS FOR EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE
Aftab (2012) · Neuroscience International · doi:10.3844/amjnsp.2012.54.62 · Cited by 3
The Choroid Plexus and Cerebrospinal Fluid System: Roles in Neurodegenerative Diseases
Badaut, J., & Ghersi‐Egea, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801740-1.00008-1 · Cited by 5
Kelley, B. J., & Petersen, R. C. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581410.013 · Cited by 4
Biazotto, F. D. O. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.11.2014.tde-10112014-112458 · Cited by 6
Metadata
- Authors
- Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., & Hampel, H.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Kuopio University Hospital (FI)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 3035-3041
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145450560
- Cited by
- 586
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 38 · 2020: 40 · 2019: 44 · 2018: 34 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 34 · 2013: 33 · 2012: 43
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, p-tau231, cerebrospinal fluid biomarkers, neurofibrillary tangles, neuritic plaques, neocortex, frontal cortex, hippocampus, postmortem neuropathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Frontal Lobe, Hippocampus, Humans, Male, Parietal Lobe, Phosphorylation, Temporal Lobe, Biomarkers, Neurofibrillary Tangles, tau Proteins, Neocortex, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.